Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Protalex Enrolling New Cohort in PRTX-100 Trial

March 3, 2011 7:14 am | News | Comments

Protalex, Inc announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active rheumatoid arthritis.


Sanofi to Allow Genzyme Some Autonomy

March 3, 2011 7:09 am | News | Comments

French drugmaker Sanofi-Aventis SA plans to give Genzyme Corp.'s orphan drug business, which focuses on rare diseases, some autonomy once it completes its $20.1 billion acquisition of the specialty drugmaker.


J & J Recalls Surgical Sutures

March 3, 2011 7:07 am | News | Comments

Health care giant Johnson & Johnson has recalled several lots of surgical sutures in the United Kingdom because of a risk they are unsterile. The recall began in late-December but U.K. regulators recently posted a notice about the action online.


Trius' Torezolid Achieves Study Goals

March 3, 2011 7:04 am | News | Comments

Trius Therapeutics, Inc. announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections.


GeoVax Releases AIDS Vaccine Trial Results

March 3, 2011 7:00 am | News | Comments

GeoVax is developing two vaccine components, both able to produce non-infectious virus-like particles in the body of a vaccine recipient. These non-infectious particles are designed to "train" the immune system of the vaccinated person to recognize HIV.


EC Approves Esbriet for IPF

March 3, 2011 6:57 am | News | Comments

InterMune, Inc. announced that the European Commission has granted marketing authorization for Esbriet. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis.


Infinity Begins Chondrosarcoma Trial

March 3, 2011 6:54 am | News | Comments

Infinity Pharmaceuticals, Inc. announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma.


DURATION-6 Study Results Released

March 3, 2011 6:48 am | News | Comments

Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes, Inc. announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON, an investigational type 2 diabetes therapy, to daily Victoza.


Virtual Slide System

March 2, 2011 6:27 am | Product Releases | Comments

The VS800 virtual slide system from Olympus allows researchers to scan and review microscope slides in just minutes. The self-contained, eyepiece-free system offers customized proprietary Olympus optics for the highest quality scans.


Interferon ELISA Kit

March 2, 2011 6:22 am | Product Releases | Comments

PBL InterferonSource has launched the VeriPlex Human Interferon Multiplex ELISA kit, which allows simultaneous quantifying of Human Type I, II, and III interferons as well as related pro-inflammatory cytokines from a single biological sample.


VaxInnate Wins $196M Flu Contract

March 2, 2011 6:05 am | News | Comments

VaxInnate Corporation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.


ACT Files SPA with FDA

March 2, 2011 5:59 am | News | Comments

ACT Biotech, Inc. has filed a special protocol assessment with the U.S. Food and Drug Administration related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.


Study Links Vitamin D to Lung Cancer Survival

March 2, 2011 5:56 am | News | Comments

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.


New Findings on Drug Delivery with Nanoparticles

March 2, 2011 5:54 am | News | Comments

Researchers have shown that medicine designed at nanoscale offers unprecedented opportunities for targeted treatment of serious diseases such as cancer. However, research also shows that the body's immune system plays a part in the drug delivery process.


Merck Receives CRL for Cladribine

March 2, 2011 5:50 am | News | Comments

Merck KGaA has received a complete response letter from the U.S. Food and Drug Administration on the new drug application for Cladribine Tablets, its investigational oral formulation of cladribine, a therapy for relapsing-remitting multiple sclerosis.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.